Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.